Generium

International Biotechnology Center Generium LLC (MBC Generium) is a private research company that was established in May 2011. The company's mission is to develop and introduce innovative, effective and safe medicines into production.

History

2024: Pharma Generium built a plant in Moscow for billions of rubles

On May 7, 2024, it became known about the completion of the construction of the pharmaceutical plant of the Generium-Next company in Moscow. This enterprise will produce drugs for the treatment of bronchial asthma, cardiovascular, rare and hereditary diseases. Read more here.

2023: The first tissue engineering product in Russia is presented

In mid-July 2023, the Generium company announced the creation of the first fabric engineering product in Russia. We are talking about a technology for the restoration of cartilage tissue based on the use of an autologous cell product - cells of the patient's own cartilage.

It is noted that the products of cell therapy, which are cultured human cells, belong to one of the most modern areas of medicine - regenerative medicine. Its main task is to restore the function of affected organs or tissues in cases where the body's own regenerative capabilities are limited. This can be, in particular, damage to the cartilage of the knee joint with the formation of a defect - a common problem that occurs in many people. In the absence of treatment, osteoarthritis can develop - a chronic disease, which is characterized by the destruction of cartilage tissue, bone growth, joint pain and a decrease in its function.

Presented the first product of tissue engineering in the Russian Federation

Autologous chondrocyte transplant surgery is performed in two stages. On the first, small pieces of cartilage are taken from the zone of the joint, which is not subjected to load, from which cartilage cells are isolated. These cells are expanded under special conditions and then, at the second stage, transplanted into the defect area, after which cartilaginous tissue is restored in its place.

The method developed by scientists of the company "Generium" provides for the removal of a section of healthy cartilage tissue through arthroscopy. The resulting cells are scaled and formed into chondrospheres, then injected into the patient. The spheres grow on the surface of the defect and gradually form a new healthy tissue. The method is minimally invasive, after a short rehabilitation, the patient can lead an ordinary life, "said Dmitry Kudlai, Deputy General Director of Generium, Corresponding Member of the Russian Academy of Sciences.

Biomedical cell product "Generium" are spheroids from autologous human chondrocytes bound by a matrix. They form without any external influences by the chondrocytes themselves. The product is suitable for repairing cartilage defects with an area of ​ ​ up to 10 square centimeters.^[1]

2022: Sale of 50% of the network of clinics "Lotus"

As it became known at the end of January 2022, MedInvestGroup bought 50% of the Chelyabinsk network of Lotus clinics. The company Generium (the manufacturer of the Sputnik V vaccine), founded by the owner of Pharmstandard, billionaire Viktor Kharitonin, sold its share. The value of the transaction was not disclosed. Read more here.

2020: Obtaining the right to produce a vaccine against coronavirus COIVD-19 Sputnik V

On October 26, 2020, it became known that the Ministry of Health of the Russian Federation issued a registration certificate to the research and production company Generium, giving it the right to produce a vaccine against the coronavirus COVID-19 Sputnik V.

The competencies of Generium made it possible to implement such a technologically complex project as scaling up the production of a new, world-first vaccine against coronavirus in a short time, and if it reaches full capacity, the company's site will be able to produce from 60 to 100 million doses of vaccine per year, - said the head of the Ministry of Industry and Trade Denis Manturov, whose words are quoted by the press service of the department.

The Sputnik V vaccine has another manufacturer - the Generium company

According to the minister, the company uses state support tools to expand production competencies. Thus, with the involvement of concessional loans from the Industrial Development Fund, Generium organizes the release of rapid test kits for detecting coronavirus, and expands the production of drugs for the treatment of hereditary diseases and asthma.

According to Daniil Talyansky, a member of the board of directors of Generium, over 90 thousand doses have already been produced. By the end of October 2020, work is also underway to gradually increase production capacity with access to indicators from 5 million to 8 million doses per month, Talyansky said.

Earlier, the right to produce this drug was granted to the branch of the Medgamal company of the Gamaleya center and Binnopharm JSC, the Ministry of Health noted.

According to the ministry, the new production sites will significantly increase the volume of vaccine produced and, accordingly, the number of Russians who can be vaccinated against the new infection.

Earlier, Denis Manturov said that the production volumes of the Sputnik V vaccine in Russia by the end of 2020 are planned to increase to one and a half million doses. After the start of mass production of the drug in Russia, universal vaccination against coronavirus will begin.^[2] SPUTNIK V

2015

As part of the project, the company will launch the production of a drug for the treatment of arthritis, which, thanks to the localization of production, will cost several tens of percent cheaper than its foreign counterpart. In addition, the created production facilities will be used for the production of promising monoclonal antibody and enzyme preparations, which are currently being developed by the applicant.

Drugs that will be produced in the created production have significant export potential. It is planned to subsequently launch the drugs on the markets of Latin America, Africa, the Middle East and Asia.

Historically (since Soviet times), a biotechnological cluster has been located on the territory of the village of Volginsky, which has formed a local labor market for specialists with experience in biotechnological production. During the implementation of the project, it is planned to create 40 new high-tech jobs.

The project cost is 1.3 billion rubles, of which 500 million may be a loan from the Industrial Development Fund.

Notes